Manufacturability is treated as an afterthought right now, but as we’ve seen in other industries, if you can bring some of those constraints earlier into the process it can have serious economic implications.
The opportunity for manufacturing innovation is growing, as the next generation of monoclonal antibodies are even more difficult to produce at scale.
The opportunity for manufacturing innovation is growing, as the next generation of monoclonal antibodies are even more difficult to produce at scale.